The verdict
Our read at a glance.
Whether survodutide's dual glucagon and GLP-1 approach delivers durable obesity and liver-disease benefits in larger trials and leads to approval.
- The signal
- Phase 2 trials have reported weight loss in obesity and improvement in metabolic liver disease (MASH) markers, with later-stage studies in progress. As an investigational drug, its full efficacy and safety remain to be established.
- The unknown
- Whether its weight and liver benefits hold up against tolerability in larger trials, and how it compares with GLP-1 and triple-agonist drugs.
- Our read
- An investigational dual agonist for obesity and liver disease, not yet proven or approved. Survodutide's Phase 2 data are early, and until late-stage results and any approval it should be read as investigational.
The mechanism
How it works.
Survodutide is an injectable peptide that activates two receptors at once: the GLP-1 receptor and the glucagon receptor. Through GLP-1 it signals the brain to reduce appetite and helps the pancreas control blood sugar, and through glucagon it raises energy expenditure and pushes the liver to burn stored fat. Activating both is the rationale for testing it in obesity and in fatty liver disease (MASH), but it is investigational, so these effects are still being measured in trials rather than established.
Safety & regulatory boundary
The consequential part.
Survodutide is investigational and not an approved product. Its safety profile, including gastrointestinal effects and the heart-rate and other effects seen with glucagon-containing agonists, is still being characterized. Research-labeled or compounded survodutide is not an approved product, and its development status does not support use outside trials.
What's next
What we're watching.
Phase 3 obesity and MASH results, regulatory filings, and comparisons with other incretin and dual or triple agonists.
Context
Why this is discussed.
Survodutide is one of the dual-agonist obesity drugs in development, of particular interest because adding glucagon activity may help with liver fat as well as weight.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · PHASE3 · ACTIVE_NOT_RECRUITING · 2023-11-20
ClinicalTrials.gov · PHASE3 · RECRUITING · 2024-11-07
ClinicalTrials.gov · PHASE3 · RECRUITING · 2024-09-17
ClinicalTrials.gov · PHASE1 · RECRUITING · 2024-10-01
ClinicalTrials.gov · PHASE1 · ACTIVE_NOT_RECRUITING · 2025-03-26
ClinicalTrials.gov · PHASE3 · COMPLETED · 2024-02-06
ClinicalTrials.gov · PHASE3 · COMPLETED · 2024-04-02
ClinicalTrials.gov · PHASE3 · COMPLETED · 2024-01-16
Indexed literature (PubMed)12
Sanyal AJ et al. · N Engl J Med · 2024
Drucker DJ · Diabetes Care · 2024
Souza M et al. · Hepatology · 2025
Kokkorakis M et al. · Pharmacol Rev · 2025
le Roux CW et al. · Lancet Diabetes Endocrinol · 2024
Wang Y et al. · J Clin Endocrinol Metab · 2025
Stefanakis K et al. · Metabolism · 2024
Newsome PN et al. · J Clin Invest · 2025
Singh A et al. · World J Gastroenterol · 2024
Blüher M et al. · Diabetologia · 2024
Rubio-Herrera MA et al. · Med Clin (Barc) · 2025
Zafer M et al. · Aliment Pharmacol Ther · 2025
Keep reading